IDEAYA Biosciences(IDYA)
Focus: IDEAYA Biosciences is a public oncology-focused biotech company developing personalized synthetic medicines, operating at mid-cap scale (~750 employees) with a clinical-stage pipeline targeting solid tumors and melanoma.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
501-1000
Open Jobs
12+13 this month
Growing — net +13 jobs in 30d
43 jobs added vs 30 removed. Steady team buildout.
Should You Work at IDEAYA Biosciences?
AI assessmentBest suited for scientists and clinical professionals willing to accept high execution risk in exchange for equity upside and meaningful oncology research; commercial professionals should assess whether pre-approval scaling justifies joining ahead of Phase 3 data readouts.
Why Work Here
- Access to advancing oncology pipeline with Phase 3 data expected soon (Darovasertib in uveal melanoma adjuvant setting with Servier partnership).
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$23M
Pipeline & Clinical Trials
IDE892
NSCLC AdenocarcinomaClinical Trials (1)
NCT07277413A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Phase 1Help build intelligence for IDEAYA Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.